Please login to the form below

Not currently logged in

EC approves Venclyxto-based combinations for newly diagnosed AML

The treatment is approved for newly diagnosed acute myeloid leukaemia patients who can’t receive intensive chemotherapy

The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who can’t receive intensive chemotherapy. 

The new approval is based on two studies – the phase 3 VIALE-A and phase 1/2 M14-358 studies of Venclyxto (venetoclax) plus hypomethylating agents in adults with newly diagnosed AML who are ineligible for intensive chemotherapy.

In the VIALE-A study, Venclyxto plus azacytidine reduced the risk of death by 34% compared to azacytidine alone, with a median overall survival of 14.7 months in the Venclyxto group compared to 9.6 months in the control group.

In addition, the Venclyxto combination more than doubled the rate of complete responses (CRs), with a CR rate of 37% compared to 18% in the control arm.

The Venclyxto plus azacytidine treatment combination also resulted in higher rates of composite complete remission – 66% compared to 28% for the control group.

The most common adverse events were mostly haematology and gastrointestinal in nature, with the most frequent serious adverse reactions being febrile neutropenia and pneumonia.

On top of the VIALE-A study, results from the M14-358 trial found that patients receiving Venclyxto in combination with decitabine achieved a CR and CR with incomplete blood count recovery (CRi) of 74%.

“This Venclyxto approval is a critical step in providing new therapeutic options for patients in the EU newly diagnosed with AML who cannot tolerate the side effects of, or are ineligible for, intensive chemotherapy,” said Levi Garraway, chief medical officer and head of global product development, Roche.

“Venclyxto-based combinations continue to show meaningful clinical benefits in AML patients, who would otherwise have a poor prognosis,” he added.

In the US, Venclyxto is approved as Venclexta in combination with azacitidine, decitabine, or low dose cytarabine for the treatment of newly diagnosed AML in adults aged 75 years and older, or who have comorbidities that prevent the use of intensive induction chemotherapy.

Venclyxto/Venclexta is a targeted medicine designed to inhibit the B-cell lymphoma-2 (BCL-2) protein.

In some blood cancers, such as AML, this protein builds up and can prevent cancer cells from self-destructing (apoptosis).

By blocking the BCL-2 protein, Venclyxto helps to restore the process of apoptosis, resulting in cancer cell death.

Article by
Lucy Parsons

26th May 2021

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....